NeurAxis (NRXS) Competitors

$7.91 -0.36 (-4.35%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$7.94 +0.04 (+0.44%)

As of 04:13 AM Eastern

NRXS vs. DCTH, CV, CLPT, RXST, and TLSI

Should you buy NeurAxis stock or one of its competitors? MarketBeat compares NeurAxis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeurAxis include Delcath Systems (DCTH), CapsoVision (CV), ClearPoint Neuro (CLPT), RxSight (RXST), and TriSalus Life Sciences (TLSI). These companies are all part of the "medical equipment" industry.

How does NeurAxis compare to Delcath Systems?

NeurAxis (NASDAQ:NRXS) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 26.4% of NeurAxis shares are owned by insiders. Comparatively, 19.4% of Delcath Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Delcath Systems has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$3.57M	25.50	-$14.63M	-$0.94	N/A
Delcath Systems	$85.23M	4.70	$2.70M	$0.01	1,161.00

In the previous week, Delcath Systems had 13 more articles in the media than NeurAxis. MarketBeat recorded 19 mentions for Delcath Systems and 6 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.41 beat Delcath Systems' score of 0.09 indicating that NeurAxis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Delcath Systems	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeurAxis has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

NeurAxis currently has a consensus target price of $13.00, indicating a potential upside of 64.35%. Delcath Systems has a consensus target price of $22.50, indicating a potential upside of 93.80%. Given Delcath Systems' higher possible upside, analysts plainly believe Delcath Systems is more favorable than NeurAxis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Delcath Systems has a net margin of 0.62% compared to NeurAxis' net margin of -492.76%. Delcath Systems' return on equity of 0.51% beat NeurAxis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Delcath Systems	0.62%	0.51%	0.46%

Summary

Delcath Systems beats NeurAxis on 11 of the 16 factors compared between the two stocks.

How does NeurAxis compare to CapsoVision?

NeurAxis (NASDAQ:NRXS) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

11.8% of NeurAxis shares are owned by institutional investors. 26.4% of NeurAxis shares are owned by company insiders. Comparatively, 2.3% of CapsoVision shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

NeurAxis has higher earnings, but lower revenue than CapsoVision. NeurAxis is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$3.57M	25.50	-$14.63M	-$0.94	N/A
CapsoVision	$13.55M	25.75	-$25.32M	-$2.19	N/A

In the previous week, NeurAxis had 5 more articles in the media than CapsoVision. MarketBeat recorded 6 mentions for NeurAxis and 1 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.87 beat NeurAxis' score of 0.41 indicating that CapsoVision is being referred to more favorably in the news media.

Company	Overall Sentiment
NeurAxis	Neutral
CapsoVision	Very Positive

NeurAxis currently has a consensus target price of $13.00, indicating a potential upside of 64.35%. CapsoVision has a consensus target price of $8.50, indicating a potential upside of 21.43%. Given NeurAxis' stronger consensus rating and higher probable upside, equities analysts plainly believe NeurAxis is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

CapsoVision has a net margin of 0.00% compared to NeurAxis' net margin of -492.76%.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
CapsoVision	N/A	N/A	N/A

Summary

NeurAxis and CapsoVision tied by winning 7 of the 14 factors compared between the two stocks.

How does NeurAxis compare to ClearPoint Neuro?

ClearPoint Neuro (NASDAQ:CLPT) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, ClearPoint Neuro had 2 more articles in the media than NeurAxis. MarketBeat recorded 8 mentions for ClearPoint Neuro and 6 mentions for NeurAxis. ClearPoint Neuro's average media sentiment score of 0.46 beat NeurAxis' score of 0.41 indicating that ClearPoint Neuro is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ClearPoint Neuro presently has a consensus target price of $18.00, indicating a potential upside of 47.66%. NeurAxis has a consensus target price of $13.00, indicating a potential upside of 64.35%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts plainly believe NeurAxis is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by insiders. Comparatively, 26.4% of NeurAxis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ClearPoint Neuro has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, NeurAxis has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

ClearPoint Neuro has a net margin of -69.08% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-69.08%	-122.17%	-40.69%
NeurAxis	-492.76%	N/A	-641.25%

NeurAxis has lower revenue, but higher earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	9.89	-$25.54M	-$0.91	N/A
NeurAxis	$3.57M	25.50	-$14.63M	-$0.94	N/A

Summary

ClearPoint Neuro and NeurAxis tied by winning 8 of the 16 factors compared between the two stocks.

How does NeurAxis compare to RxSight?

RxSight (NASDAQ:RXST) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, RxSight had 3 more articles in the media than NeurAxis. MarketBeat recorded 9 mentions for RxSight and 6 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.41 beat RxSight's score of -0.25 indicating that NeurAxis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

RxSight presently has a consensus target price of $9.44, indicating a potential upside of 70.17%. NeurAxis has a consensus target price of $13.00, indicating a potential upside of 64.35%. Given RxSight's higher possible upside, research analysts plainly believe RxSight is more favorable than NeurAxis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

78.8% of RxSight shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 26.4% of NeurAxis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

RxSight has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, NeurAxis has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

RxSight has a net margin of -36.58% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
NeurAxis	-492.76%	N/A	-641.25%

NeurAxis has lower revenue, but higher earnings than RxSight. NeurAxis is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.71	-$38.94M	-$1.13	N/A
NeurAxis	$3.57M	25.50	-$14.63M	-$0.94	N/A

Summary

NeurAxis beats RxSight on 9 of the 16 factors compared between the two stocks.

How does NeurAxis compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, TriSalus Life Sciences had 3 more articles in the media than NeurAxis. MarketBeat recorded 9 mentions for TriSalus Life Sciences and 6 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.41 beat TriSalus Life Sciences' score of -0.17 indicating that NeurAxis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TriSalus Life Sciences has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, NeurAxis has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by insiders. Comparatively, 26.4% of NeurAxis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NeurAxis has lower revenue, but higher earnings than TriSalus Life Sciences. NeurAxis is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	3.63	-$39.23M	-$1.83	N/A
NeurAxis	$3.57M	25.50	-$14.63M	-$0.94	N/A

TriSalus Life Sciences presently has a consensus target price of $7.50, indicating a potential upside of 180.90%. NeurAxis has a consensus target price of $13.00, indicating a potential upside of 64.35%. Given TriSalus Life Sciences' higher possible upside, research analysts plainly believe TriSalus Life Sciences is more favorable than NeurAxis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

TriSalus Life Sciences has a net margin of -60.85% compared to NeurAxis' net margin of -492.76%.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-85.34%
NeurAxis	-492.76%	N/A	-641.25%

Summary

NeurAxis beats TriSalus Life Sciences on 8 of the 15 factors compared between the two stocks.

Get NeurAxis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRXS vs. The Competition

Export

Metric	NeurAxis	Electromedical equipment Industry	Medical Sector	NASDAQ Exchange
Market Cap	$91.01M	$74.16M	$6.30B	$12.20B
Dividend Yield	N/A	N/A	2.79%	5.30%
P/E Ratio	-4.30	7.57	21.00	25.58
Price / Sales	25.50	199.83	554.55	78.84
Price / Cash	N/A	41.36	42.94	55.34
Price / Book	-29.30	6.26	9.75	6.66
Net Income	-$14.63M	-$5.50M	$3.55B	$333.63M
7 Day Performance	-10.11%	-1.85%	-0.53%	-0.11%
1 Month Performance	10.17%	20.43%	1.20%	3.94%
1 Year Performance	248.46%	244.68%	41.22%	36.07%

NeurAxis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRXS NeurAxis	3.0375 of 5 stars	$7.91 -4.4%	$13.00 +64.3%	+243.9%	$91.01M	$3.57M	N/A	19	Gap Down
DCTH Delcath Systems	2.2019 of 5 stars	$11.26 -2.3%	$22.50 +99.8%	-24.1%	$397.26M	$85.23M	160.86	60	Earnings Report Analyst Downgrade Analyst Revision High Trading Volume
CV CapsoVision	1.522 of 5 stars	$7.01 -0.7%	$8.50 +21.3%	N/A	$351.94M	$13.55M	N/A	90
CLPT ClearPoint Neuro	2.1446 of 5 stars	$11.47 +3.3%	$14.50 +26.4%	-14.2%	$332.85M	$36.97M	N/A	110	News Coverage Earnings Report
RXST RxSight	2.7033 of 5 stars	$6.78 -6.6%	$9.78 +44.2%	-58.0%	$300.54M	$134.48M	N/A	220	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRXS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeurAxis (NRXS) Competitors

NRXS vs. DCTH, CV, CLPT, RXST, and TLSI

How does NeurAxis compare to Delcath Systems?

Summary

How does NeurAxis compare to CapsoVision?

Summary

How does NeurAxis compare to ClearPoint Neuro?

Summary

How does NeurAxis compare to RxSight?

Summary

How does NeurAxis compare to TriSalus Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXS vs. The Competition

NeurAxis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeurAxis (NRXS) Competitors

NRXS vs. DCTH, CV, CLPT, RXST, and TLSI

How does NeurAxis compare to Delcath Systems?

Do insiders & institutionals hold more shares of NRXS or DCTH?

Which has preferable valuation and earnings, NRXS or DCTH?

Does the media prefer NRXS or DCTH?

Which has more volatility and risk, NRXS or DCTH?

Do analysts prefer NRXS or DCTH?

Is NRXS or DCTH more profitable?

Summary

How does NeurAxis compare to CapsoVision?

Do institutionals & insiders hold more shares of NRXS or CV?

Which has better valuation & earnings, NRXS or CV?

Does the media favor NRXS or CV?

Do analysts rate NRXS or CV?

Is NRXS or CV more profitable?

Summary

How does NeurAxis compare to ClearPoint Neuro?

Does the media refer more to CLPT or NRXS?

Do analysts recommend CLPT or NRXS?

Do insiders and institutionals believe in CLPT or NRXS?

Which has more risk and volatility, CLPT or NRXS?

Is CLPT or NRXS more profitable?

Which has stronger valuation & earnings, CLPT or NRXS?

Summary

How does NeurAxis compare to RxSight?

Does the media refer more to RXST or NRXS?

Do analysts recommend RXST or NRXS?

Do insiders and institutionals believe in RXST or NRXS?

Which has more risk and volatility, RXST or NRXS?

Is RXST or NRXS more profitable?

Which has stronger valuation & earnings, RXST or NRXS?

Summary

How does NeurAxis compare to TriSalus Life Sciences?

Does the media refer more to TLSI or NRXS?

Which has more risk and volatility, TLSI or NRXS?

Do insiders and institutionals believe in TLSI or NRXS?

Which has stronger valuation & earnings, TLSI or NRXS?

Do analysts recommend TLSI or NRXS?

Is TLSI or NRXS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXS vs. The Competition

NeurAxis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools